National Comprehensive Cancer Network

About NCCN

NCCN 18th Annual Conference Fellows Program

On March 13, 2013, 60 fellows attended the NCCN 2013 Fellows Recognition Program: New Horizons in Quality Cancer Care™ during the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™ in Hollywood, Florida.

The half-day, meeting began with a presentation from Louis Burt Nabors, MD, University of Alabama at Birmingham Comprehensive Cancer Network, regarding systemic therapy for primary central nervous system cancers. Dr. Nabors provided general background on the variety of primary brain tumors, including meningioma, primary central nervous system lymphoma, and glioma, expanding upon biological mechanisms responsible for cellular behaviors that drive morbidity and mortality for those diseases.

Following Dr. Nabors, Al B. Benson, III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discussed emerging treatment for hepatobiliary cancers, such a sorafenib and tivantinib therapies and chemoembolization using sorafenib, and Margaret von Mehren, MD, Fox Chase Cancer Center, presented targeted therapies for sarcomas, including imatinib and sunitinib in gastrointestinal stromal tumors and crizotinib in immunofibroblastic tumors.

Classification of myelodysplastic syndrome (MDS), risk adapted therapy for MDS, and acute myeloid leukemia (AML) were the focus of a presentation given by Rafel Bejar, MD, PhD, UC San Diego Moores Cancer Center. Dr. Bejar discussed various prognostic scoring systems for MDS/AML, as well as treatment options, including stem cell transplantation, immune suppression, and red blood cell transfusion.

The program concluded with a presentation on molecular profiling to identify tissue of origin in occult primary cancers from David S. Ettinger, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Charles R. Handorf, MD, PhD, University of Tennessee Health Science Center. In addition to a general overview of occult primary cancers, Drs. Ettinger and Handorf discussed the value of immunohistochemistry in determining primary disease sites, as well as integration of molecular profiling in determination of treatment for patients with occult primary tumors.

NCCN plans to hold the next NCCN Fellows Program during the NCCN 19th Annual Conference in March 2014.